Cargando…

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021

The safety profile of the 9-valent human papillomavirus vaccine (9vHPV) was evaluated based on the reporting rate of adverse events following immunization (AEFI) obtained from the passive surveillance data in Zhejiang. The 9vHPV AEFI reports in Zhejiang were collected and reviewed from the National...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Fuxing, Pan, Xuejiao, Liang, Hui, Shen, Lingzhi, Wang, Ying, Chen, Yaping, Lv, Huakun, Hu, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	HPV – Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762803/ https://www.ncbi.nlm.nih.gov/pubmed/36484114 http://dx.doi.org/10.1080/21645515.2022.2152256

Ejemplares similares

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
por: Sundaram, Maria E., et al.
Publicado: (2022)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China
por: Hu, Yu, et al.
Publicado: (2022)

Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province，China
por: Yuan, Haowen, et al.
Publicado: (2023)

Human papillomavirus vaccination at the first opportunity: An overview
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China
por: Wang, Tianyu, et al.
Publicado: (2023)

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
por: Ellingson, Mallory K., et al.
Publicado: (2023)

Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study
por: Amend, Kandace L., et al.
Publicado: (2022)

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
por: Chen, Linxiang, et al.
Publicado: (2023)

Barriers and facilitators in uptake of human papillomavirus vaccine across English Canada: A review
por: Khan, Amal, et al.
Publicado: (2023)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Parents’ willingness to vaccinate their daughters with human papillomavirus vaccine and associated factors in Debretabor town, Northwest Ethiopia: A community-based cross-sectional study
por: Aragaw, Getie Mihret, et al.
Publicado: (2023)

Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China
por: Pan, Xuejiao, et al.
Publicado: (2022)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
por: Saxena, Kunal, et al.
Publicado: (2023)

Engaging health plans to prioritize HPV vaccination and initiate at age 9
por: Foley, Shaylen, et al.
Publicado: (2023)

How to make effective HPV vaccine recommendations starting at age 9
por: Brewer, Noel T., et al.
Publicado: (2023)

Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10
por: Kahn, Benjamin Z., et al.
Publicado: (2023)

Implementing interventions to start HPV vaccination at age 9: Using the evidence we have
por: Brandt, Heather M., et al.
Publicado: (2023)

Recommending HPV vaccination at age 9 to reduce health disparities: Communication challenges and opportunities
por: Coyne-Beasley, Tamera, et al.
Publicado: (2023)

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
por: O’Leary, Sonja C., et al.
Publicado: (2023)

The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020
por: Minihan, Adair K., et al.
Publicado: (2023)

Perceptions and acceptability of HPV vaccination among parents of female adolescents 9–14 in China: A cross-sectional survey based on the theory of planned behavior
por: Yi, Youqin, et al.
Publicado: (2023)

Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: Success stories from two private pediatric clinics
por: Zorn, Sherri, et al.
Publicado: (2023)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China
por: Lv, Huakun, et al.
Publicado: (2022)

Medical ethics principles underscore advocating for human papillomavirus vaccine
por: Healy, C. Mary, et al.
Publicado: (2022)

Cost-effectiveness analysis of introducing rotavirus vaccine into immunization program in Zhejiang province, China: A decision tree-Markov model study
por: Lv, Huakun, et al.
Publicado: (2023)

Resumption of active recommendation of the human papillomavirus vaccine in Japan and future challenges for the National Immunization Program
por: Ujiie, Mugen
Publicado: (2022)

Social and psychological impact of HPV testing in cervical screening: a qualitative study
por: McCaffery, K, et al.
Publicado: (2006)

AN UPWARD TREND IN DNA P16INK4A METHYLATION PATTERN AND HIGH RISK HPV INFECTION ACCORDING TO THE SEVERITY OF THE CERVICAL LESION
por: Carestiato, Fernanda Nahoum, et al.
Publicado: (2013)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series
por: Kajtezovic, Sidika, et al.
Publicado: (2023)

HPV vaccine recommendations by age: A survey of providers in federally qualified health centers
por: Lake, Paige, et al.
Publicado: (2023)

Feminized vaccine? Parents’ attitudes toward HPV vaccination of adolescents in Poland: A representative study
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
por: Achdiat, Pati Aji, et al.
Publicado: (2023)

Willingness to get HPV vaccination among female university students in Kuwait and its relation to vaccine conspiracy beliefs
por: Alsanafi, Mariam, et al.
Publicado: (2023)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

HPV vaccine knowledge, attitudes, and practices among New York State medical providers, dentists, and pharmacists
por: Fernandes, Annlynn, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jk4dkdnjn0sqn39m9fts44tujm